Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:ATXSNASDAQ:SCPHNASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$1.77+10.6%$1.98$1.29▼$7.85$194.19M1.241.79 million shs2.07 million shsATXSAstria Therapeutics$4.37+3.3%$5.19$3.56▼$12.92$238.72M0.45363,415 shs872,027 shsSCPHscPharmaceuticals$2.48+1.6%$2.63$1.94▼$5.65$124.70M0.17357,938 shs291,086 shsZVRAZevra Therapeutics$7.75-1.5%$7.52$4.20▼$9.76$423.76M1.87618,257 shs464,525 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+10.28%-2.21%+18.79%-43.09%-62.74%ATXSAstria Therapeutics+3.31%-14.48%+8.17%-36.11%-55.09%SCPHscPharmaceuticals+2.48%0.00%+6.90%-25.75%-44.64%ZVRAZevra Therapeutics-1.52%-3.13%+12.32%+2.79%+60.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon1.7832 of 5 stars3.51.00.00.01.81.70.6ATXSAstria Therapeutics2.0341 of 5 stars3.71.00.00.03.41.70.0SCPHscPharmaceuticals3.5888 of 5 stars3.50.00.04.22.61.70.6ZVRAZevra Therapeutics2.7499 of 5 stars4.60.00.00.03.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$18.67954.61% UpsideATXSAstria Therapeutics 3.38Buy$30.00586.50% UpsideSCPHscPharmaceuticals 3.00Buy$14.00464.52% UpsideZVRAZevra Therapeutics 3.11Buy$22.29187.56% UpsideCurrent Analyst Ratings BreakdownLatest SCPH, ANNX, ATXS, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$47.003/20/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $12.003/20/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/13/2025ZVRAZevra TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.003/13/2025ZVRAZevra TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/13/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/12/2025ATXSAstria TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.00 ➝ $28.003/12/2025ZVRAZevra TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$18.003/12/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/12/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AATXSAstria TherapeuticsN/AN/AN/AN/A$3.33 per shareN/ASCPHscPharmaceuticals$36.33M3.43N/AN/A$1.04 per share2.38ZVRAZevra Therapeutics$23.61M17.95N/AN/A$1.71 per share4.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%N/AATXSAstria Therapeutics-$72.89M-$1.67N/AN/AN/AN/A-43.58%-29.36%N/ASCPHscPharmaceuticals-$54.81M-$1.90N/AN/AN/A-264.60%-244.93%-68.56%5/14/2025 (Estimated)ZVRAZevra Therapeutics-$46.05M-$2.24N/A38.75N/A-342.63%-159.54%-51.50%5/13/2025 (Estimated)Latest SCPH, ANNX, ATXS, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28N/AN/AN/A$11.63 millionN/A5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21N/AN/AN/A$16.96 millionN/A5/12/2025Q1 2025ANNXAnnexon-$0.30-$0.37-$0.07-$0.37N/AN/A3/19/2025Q4 2024SCPHscPharmaceuticals-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 million3/11/2025Q4 2024ATXSAstria Therapeutics-$0.45-$0.44+$0.01-$0.44N/AN/A3/11/2025Q4 2024ZVRAZevra Therapeutics-$0.39-$0.67-$0.28-$0.67$8.93 million$12.00 million3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AATXSAstria TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18ATXSAstria TherapeuticsN/A22.3822.38SCPHscPharmaceuticals1.668.086.89ZVRAZevra Therapeutics0.842.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AATXSAstria Therapeutics98.98%SCPHscPharmaceuticals89.52%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%ATXSAstria Therapeutics2.90%SCPHscPharmaceuticals5.52%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableATXSAstria Therapeutics3056.43 million54.80 millionOptionableSCPHscPharmaceuticals3050.28 million47.28 millionOptionableZVRAZevra Therapeutics2054.68 million52.10 millionOptionableSCPH, ANNX, ATXS, and ZVRA HeadlinesRecent News About These CompaniesZevra Therapeutics, Inc. Q1 2025 Earnings PreviewMay 12 at 9:36 PM | msn.comZevra Therapeutics (ZVRA) Expected to Announce Earnings on WednesdayMay 9, 2025 | marketbeat.comZevra Therapeutics Announces Details for Q1 2025 Financial Results CallMay 6, 2025 | globenewswire.comBrokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $22.29May 4, 2025 | americanbankingnews.comBarclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)May 3, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by BrokeragesMay 3, 2025 | marketbeat.com85,818 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by Boothbay Fund Management LLCMay 2, 2025 | marketbeat.comZevra Therapeutics to Participate in the Citizens Life Science ConferenceMay 1, 2025 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)April 28, 2025 | marketbeat.comGeode Capital Management LLC Has $9.91 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)April 26, 2025 | marketbeat.comDiadema Partners LP Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)April 24, 2025 | marketbeat.comZevra Files Definitive Proxy Statement and Mails Letter to StockholdersApril 21, 2025 | finance.yahoo.comZevra Therapeutics urges stockholders to vote for director nomineesApril 21, 2025 | markets.businessinsider.comZevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest ConcernsApril 21, 2025 | quiverquant.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Position Boosted by Altium Capital Management LLCApril 19, 2025 | marketbeat.comZevra Therapeutics announces publication on arimoclomolApril 18, 2025 | markets.businessinsider.comZevra Therapeutics Publishes Study on Arimoclomol's Mechanism of Action in Niemann-Pick Type C DiseaseApril 17, 2025 | quiverquant.comZevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and MetabolismApril 17, 2025 | globenewswire.comVanguard Group Inc. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)April 17, 2025 | marketbeat.comZevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionApril 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCPH, ANNX, ATXS, and ZVRA Company DescriptionsAnnexon NASDAQ:ANNX$1.77 +0.17 (+10.63%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.76 -0.01 (-0.56%) As of 05/12/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Astria Therapeutics NASDAQ:ATXS$4.37 +0.14 (+3.31%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$4.36 -0.01 (-0.23%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.scPharmaceuticals NASDAQ:SCPH$2.48 +0.04 (+1.64%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$2.47 -0.01 (-0.40%) As of 05/12/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Zevra Therapeutics NASDAQ:ZVRA$7.75 -0.12 (-1.52%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$7.76 +0.01 (+0.19%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
